104.97
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Axsome Therapeutics (NASDAQ:AXSM) Trading Down 5.6%Here's What Happened - MarketBeat
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s 4th Largest Position - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Mizuho reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit - TipRanks
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund - MarketBeat
Lindbrook Capital LLC Sells 14,103 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What analysts say about Axsome Therapeutics Inc. stockExtraordinary market timing - jammulinksnews.com
Axsome Therapeutics Inc. Stock Analysis and ForecastUnstoppable trading performance - Autocar Professional
Axsome Therapeutics Rings the Opening Bell - Nasdaq
Axsome Therapeutics hosts frontiers in Brain Health R&D Day - TipRanks
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - Lelezard
Axsome Therapeutics: A CNS Pipeline with High-Impact Catalysts for Long-Term Growth - AInvest
Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation - Nasdaq
Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments - Stock Titan
Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline - Stock Titan
Bank of New York Mellon Corp Has $15.28 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Issues Negative Outlook for AXSM Earnings - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Mizuho reiterates Outperform rating on Axsome Therapeutics stock ahead of R&D Day - Investing.com Australia
Edgestream Partners L.P. Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 4.5% this past week - simplywall.st
Alps Advisors Inc. Has $3.78 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Long Term Investment Analysis - news.stocktradersdaily.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Iridian Asset Management LLC CT - MarketBeat
Penserra Capital Management LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Stocks Showing Improving Market Leadership: Axsome Therapeutics Earns 85 RS Rating - MSN
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating - MSN
Axsome Therapeutics (AXSM) Soars 5.77% on Positive Analyst Ratings - AInvest
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 - 富途牛牛
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - The Manila Times
Axsome Therapeutics Scheduled to Report Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Nasdaq
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics shares rise 1.08% intraday as RBC Capital Markets maintains its stance on the biopharma company. - AInvest
Axsome Therapeutics (AXSM) Initiated with a Buy at Oppenheimer - The Globe and Mail
Axsome Therapeutics (AXSM) Gets a Buy from Wells Fargo - The Globe and Mail
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $184 - 富途牛牛
Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle - MSN
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):